307 results on '"Paulden, Mike"'
Search Results
2. A Framework for the Fair Pricing of Medicines
3. Outcomes of Prophylactic Peritoneal Dialysis Catheter Insertion in Children Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis
4. Logical Inconsistencies in the Health Years in Total and Equal Value of Life-Years Gained
5. Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups
6. Economic Evaluation of Sucrose Octasulfate Dressing for Treatment of Diabetic Foot Ulcers in Patients with Type 2 Diabetes
7. Small differences in EQ-5D-5L health utility scores were interpreted differently between and within respondents
8. Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates
9. Optimization of an adult immunization program in Canada
10. Decision Makers Should Avoid the Health Years in Total (HYT) Approach: A Response to Dr Basu
11. Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial
12. Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer's Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated.
13. The health and financial impacts of a sugary drink tax across different income groups in Canada
14. Modifying NICE’s Approach to Equity Weighting
15. NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests
16. Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier
17. Calculating and Interpreting ICERs and Net Benefit
18. Why it’s Time to Abandon the ICER
19. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer
20. One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
21. Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model
22. We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment.
23. A Framework for the Fair Pricing of Medicines
24. Logical Inconsistencies in the Health Years in Total and Equal Value of Life-Years Gained
25. OP47 The Risk-Based Price: Incorporating Uncertainty And Risk Attitudes In Health Technology Pricing
26. Challenges of calculating cost-effectiveness thresholds
27. Incorporating equity in economic evaluations: a multi-attribute equity state approach
28. Direct equity weights
29. Author Reply
30. We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment
31. Life at a Premium: Considering an End-of-Life Premium in Value-Based Reimbursement
32. Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process
33. Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models
34. Which interventions are cost-effective for the management of whiplash-associated and neck pain-associated disorders? A systematic review of the health economic literature by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration
35. A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models
36. Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
37. Correction to: Calculating and Interpreting ICERs and Net Benefit
38. Prediction of odds for emergency cesarean section: A secondary analysis of the CHILD term birth cohort study
39. NICE’s Selective Application of Differential Discounting: Ambiguous, Inconsistent, and Unjustified
40. Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration
41. Cancer Drugs Fund 2.0: A Missed Opportunity?
42. Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer
43. Housing for vulnerable populations—identifying system cost implications: an analytic literature review.
44. Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
45. Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates
46. sj-docx-1-mdm-10.1177_0272989X221097106 – Supplemental material for Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates
47. Screening for postnatal depression in primary care: cost effectiveness analysis
48. How Valuable are Multiple Treatment Comparison Methods in Evidence-Based Health-Care Evaluation?
49. Some Inconsistencies in NICE’s Consideration of Social Values
50. Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.